FDCDDQ
KLRA

Federation des caisses Desjardins du Quebec’s Kailera Therapeutics KLRA Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio KLRA Stock Details KLRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.3K Buy
+1,150
New +$25.3K ﹤0.01% 2123

Other funds holding KLRA

BCI
Bain Capital Investors Boston, Massachusetts $4.82B AUM 35.43% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's KLRA Position: Q2 2026 in Review

Federation des caisses Desjardins du Quebec opened a new position in Kailera Therapeutics (KLRA) in Q2 2026: 1,150 shares worth $25.3K. The stake represents ﹤0.01% of the portfolio and ranks #2123 among its holdings.

99 funds tracked by Wall St. Rank hold KLRA as of Q2 2026.

  • Federation des caisses Desjardins du Quebec held 1,150 shares of Kailera Therapeutics worth $25.3K as of Q2 2026.
  • Kailera Therapeutics was a new Federation des caisses Desjardins du Quebec position in Q2 2026.
  • Kailera Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q2 2026, its #2123 holding.
  • 99 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q2 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q2 2026, filed 14 Aug 2026.